Biotech Values

[floblu14]

MNTA European/U.S. Patent Applications Update for RMF - Plus MNTA Overview of their Patent Estate -

1. METHODS OF ASSESSING ACTIVITY OF A POLYSACCHARIDE COMPOSITIONS 2010-10-21

Abstract:
Methods of assessing polysaccharide preparations lacking substantial anticoagulant activity are provided herein

http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_V3&FT=D&date=20101021&CC=WO&NR=2010121196A1&KC=A1

2. CONTROL OF COPOLYMER COMPOSITIONS 2010-10-07

Abstract:
Methods of making copolymers are described.

http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_V3&FT=D&date=20101007&CC=US&NR=2010256039A1&KC=A1


3. METHODS RELATED TO CELL SURFACE GLYCOSYLATION 2010-8-5

Abstract:
The present disclosure provides methods for assessing the glycosylation of a target glycoprotein produced by a cell through analysis of cell-surface glycans on the cell. The present disclosure therefore teaches that glycosylation of cell surface proteins can serve as a proxy for glycosylation of other proteins.

http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_V3&FT=D&date=20100805&CC=US&NR=2010196940A1&KC=A1

4. GALACTOSE-ALPHA-1, 3-GALACTOSE-CONTAINING N-GLYCANS IN GLYCOPROTEIN PRODUCTS DERIVED FROM CHO CELLS 2010-7-29

Abstract:
The present invention provides methods for evaluating a Chinese Hamster Ovary (CHO) cell population by measuring glycans containing terminal galactose-alpha-1-3-galactose residues produced by said cells, wherein the CHO cells have not been genetically engineered to express an alpha-galactosyl transferase coding sequence.

http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_V3&FT=D&date=20100729&CC=WO&NR=2010085251A1&KC=A1

5. COMPARATIVE ANALYSIS OF PROTEIN CONFORMATIONS BY USING 2D NOESY NMR SPECTRA 2010-7-29

Abstract:
The present disclosure provides a method for determining the relative conformations of a protein provided in different protein preparations, comprising steps of: (i) obtaining a first 2D NOESY NMR spectrum of a first protein preparation; (ii) obtaining a second 2D NOESY NMR spectrum of a second protein preparation; and (iii); determining whether a protein has a different conformation in the first and second protein preparations by comparing one or more cross-peaks in the first 2D NOESY NMR spectrum with one or more corresponding cross-peaks in the second 2D NOESY NMR spectrum.

http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_V3&FT=D&date=20100729&CC=US&NR=2010188084A1&KC=A1

6. NON-ANTICOAGULANT POLYSACCHARIDE COMPOSITIONS 2010-7-21

Abstract:
Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.

http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_V3&FT=D&date=20100721&CC=EP&NR=2207811A1&KC=A1

7. METHODS RELATED TO MODIFIED GLYCANS 2010-6-24

Abstract:
Among other things, the present disclosure provides methods for enriching, identifying, and/or quantifying unusually modified glycans (e.g., phosphorylated glycans, sulfated glycans, and/or multi-acetylated glycans). In many embodiments, methods comprise providing a glycan preparation from which sialic acids have been released; subjecting the sialidase-treated glycan preparation to a separation technique that separates glycans based on charge-to-mass ratio; and quantifying the charged products using at least one quantification standard.

http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_V3&FT=D&date=20100624&CC=WO&NR=2010071824A2&KC=A2

8. CHARACTERIZATION OF O-LINKED GLYCANS 2010-6-24

Abstract:
The present disclosure provides methods for analyzing structure and/or composition of glycoproteins and glycans of glycoproteins. Such methods can include subjecting a glycoprotein preparation to a condition that removes at least one O-linked glycan from the glycoprotein. Such methods can include subjecting a glycoprotein preparation to a condition that releases an N-glycan from the glycoprotein, e.g., prior to subjecting the glycoprotein to a condition that releases an O-glycan from the glycoprotein.

http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&localeenV3&FTD&date=20100624&CC=WO&NR=2010071817A2&KC=A2


PATENTS

Over 100 patents give Momenta a strong proprietary position
Momenta possesses a strong intellectual property position around our characterization platform. We license or own a total of over 100 patents and patent applications. Our patent portfolio includes claims covering:

•methods and technologies for characterizing sugars;
•the use of certain enzymes and reagents that specifically recognize polysaccharides in the characterization of sugars;
•methods and technologies for chemical and metabolic synthesis of sugars;
•the composition of matter of certain novel low-molecular-weight herapins (LMWHs), including M118, and heparinase variants;
•methods to produce and identify sugars associated with glycoproteins;
•methods to analyze and monitor glycoprotein profiles for purposes associated with the diagnosis, staging, prognosis and monitoring of cancer; and
•methods for the in vivo non-invasive delivery of sugars.
We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position

http://www.momentapharma.com/technology/patents.html